ibandronate sodium


Also found in: Dictionary.

ibandronate sodium

(ī-băn′drə-nāt′)
n.
A bisphosphonate drug that inhibits bone resorption, given monthly to treat and prevent osteoporosis primarily in postmenopausal women.
Mentioned in ?
References in periodicals archive ?
It was reported yesterday that Mylan, a global generic and specialty pharmaceuticals company, has launched Ibandronate Sodium Injection, one mg (base)/mL, packaged in three mg (base)/three mL pre-filled glass syringes.
According to IMS Health, Ibandronate Sodium Injection, one mg (base)/mL, packaged in three mg (base)/ three mL pre-filled glass syringes had US sales of about USD18.
Reddy's Ibandronate sodium tablets in 150 mg are available in cartons of 3 blister packs containing 1 tablet each (once monthly dosing).
Reddya[euro](tm)s Laboratories unveils US FDA approved Ibandronate Sodium tablets 150mg(C)2012 M2 COMMUNICATIONS http://www.
In Japan, a Phase III study was conducted in approximately 400 patients with osteoporosis to assess efficacy and safety of RG484/CT-064 oral agent against ibandronate sodium hydrate injection.
Ibandronate sodium is approved by the FDA for the treatment (2.
announced today that ibandronate sodium hydrate (generic name) oral agent demonstrated non-inferiority in efficacy of increasing the bone mass of the lumbar spine compared to a comparator, ibandronate sodium hydrate injection.
announced today that they launched the ibandronate sodium hydrate, a bisphosphonate antiresorptive agent brand name: Bonviva Injection 1 mg Syringe (hereafter, Bonviva IV Injection ) , for the indication of osteoporosis on August 29, 2013.